Drug intelligence / Profile preview

TEQ102

Development stage: Preclinical
Lead developer: Oncoteq
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TEQ102 is an antibody-drug conjugate (ADC) being developed by Oncoteq (a company seeded by Cureteq) for the treatment of CD30-positive lymphomas, including Hodgkin's lymphoma and T-cell lymphomas. Originally developed by Tubulis as TUB-010, the drug consists of an anti-CD30 antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via the proprietary TubTag® linker technology. This technology aims to provide high stability and a homogenous drug-antibody ratio, potentially improving the therapeutic index compared to existing CD30-targeted therapies. TEQ102 is currently in preclinical development and is described as IND-ready.

Targets

TUBB (Tubulin (alpha and beta subunits))CD30 (CD30 antigen)

Beyond the preview

Go deeper on TEQ102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEQ102.

Explore the full profile